Brought to you by 
Celldex buys Kolltan for $62.5mm, plus earn-outs, in stock-for-stock deal
08 Sep 2020
Executive Summary
Celldex Therapeutics Inc. issued $62.5mm of its stock to acquire privately held Kolltan Pharmaceuticals Inc. (antibody therapies for cancer). Kolltan could also receive up to $172.5mm in earn-outs based on development, regulatory, and sales achievements.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Celldex buys Kolltan for $62.5mm, plus earn-outs, in stock-for-stock deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice